Additionally, a similar study developed a multi-epitope peptide based on neoantigens that targets TLR4/MD2 as a possible vaccine against colorectal cancer, demonstrating its reliance on TLR4 binding and capacity to trigger powerful immune responses against colorectal cancer antigens (116). The gene discussed is LY96; the disease is colorectal cancer.